Orchestra BioMed Holdings, Inc. Cost of Revenue
Orchestra BioMed Holdings, Inc. (OBIO) reported Cost of Revenue of $25.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. cost of revenue for the quarter ending 2026-06-30 was $25.00K, a 45.65% decline year-over-year.
- Orchestra BioMed Holdings, Inc. cost of revenue for the quarter ending 2026-03-31 was $32.00K, a 27.27% decline year-over-year.
- Orchestra BioMed Holdings, Inc. cost of revenue for the quarter ending 2025-12-31 was $51.00K, a 12.07% decline year-over-year.
- Orchestra BioMed Holdings, Inc. cost of revenue for the quarter ending 2025-09-30 was $49.00K, a 27.94% decline year-over-year.
- Orchestra BioMed Holdings, Inc. cost of revenue for fiscal 2025 was $190.00K, a 6.86% decline from fiscal 2024.
- Orchestra BioMed Holdings, Inc. cost of revenue for fiscal 2024 was $204.00K, a 9.68% increase from fiscal 2023.
- Orchestra BioMed Holdings, Inc. cost of revenue for fiscal 2023 was $186.00K, a 11.85% decline from fiscal 2022.
- Orchestra BioMed Holdings, Inc. cost of revenue for fiscal 2022 was $211.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.00K 10-Q · filed 2026-08-10 | $57.00K 10-Q · filed 2026-08-10 | $108.00K derived: sum of 3 quarters · filed 2026-08-10 | $157.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $32.00K 10-Q · filed 2026-05-12 | $83.00K derived: sum of 2 quarters · filed 2026-05-12 | $132.00K derived: sum of 3 quarters · filed 2026-05-12 | $178.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $100.00K derived: sum of 2 quarters · filed 2026-03-12 | $146.00K derived: sum of 3 quarters · filed 2026-08-10 | $190.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $49.00K 10-Q · filed 2025-11-10 | $95.00K derived: sum of 2 quarters · filed 2026-08-10 | $139.00K 10-Q · filed 2025-11-10 | $197.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $46.00K 10-Q · filed 2026-08-10 | $90.00K 10-Q · filed 2026-08-10 | $148.00K derived: sum of 3 quarters · filed 2026-08-10 | $216.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $44.00K 10-Q · filed 2026-05-12 | $102.00K derived: sum of 2 quarters · filed 2026-05-12 | $170.00K derived: sum of 3 quarters · filed 2026-05-12 | $214.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $126.00K derived: sum of 2 quarters · filed 2026-03-12 | $170.00K derived: sum of 3 quarters · filed 2026-03-12 | $204.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $68.00K 10-Q · filed 2025-11-10 | $112.00K derived: sum of 2 quarters · filed 2025-11-10 | $146.00K 10-Q · filed 2025-11-10 | $193.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $44.00K 10-Q · filed 2025-08-12 | $78.00K 10-Q · filed 2025-08-12 | $125.00K derived: sum of 3 quarters · filed 2025-08-12 | $166.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $34.00K 10-Q · filed 2025-05-12 | $81.00K derived: sum of 2 quarters · filed 2025-05-12 | $122.00K derived: sum of 3 quarters · filed 2025-05-12 | $176.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $88.00K derived: sum of 2 quarters · filed 2025-03-31 | $142.00K derived: sum of 3 quarters · filed 2025-03-31 | $186.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $41.00K 10-Q · filed 2024-11-12 | $95.00K derived: sum of 2 quarters · filed 2024-11-12 | $139.00K 10-Q · filed 2024-11-12 | $192.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $54.00K 10-Q · filed 2024-08-12 | $98.00K 10-Q · filed 2024-08-12 | $151.00K derived: sum of 3 quarters · filed 2024-08-12 | $207.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $44.00K 10-Q · filed 2024-05-13 | $97.00K derived: sum of 2 quarters · filed 2024-05-13 | $153.00K derived: sum of 3 quarters · filed 2024-05-13 | $213.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $109.00K derived: sum of 2 quarters · filed 2024-03-27 | $169.00K derived: sum of 3 quarters · filed 2024-03-27 | $211.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | $56.00K 10-Q · filed 2023-11-13 | $116.00K derived: sum of 2 quarters · filed 2023-11-13 | $158.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $60.00K 10-Q · filed 2023-08-10 | $102.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $42.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |